Holly Knoderer

533 total citations
19 papers, 316 citations indexed

About

Holly Knoderer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Holly Knoderer has authored 19 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Surgery. Recurrent topics in Holly Knoderer's work include Advanced Breast Cancer Therapies (5 papers), Gastric Cancer Management and Outcomes (4 papers) and Metastasis and carcinoma case studies (2 papers). Holly Knoderer is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Gastric Cancer Management and Outcomes (4 papers) and Metastasis and carcinoma case studies (2 papers). Holly Knoderer collaborates with scholars based in United States, Spain and Italy. Holly Knoderer's co-authors include David A. Flockhart, Jason Robarge, Manjusha Kumar, Chad A. Knoderer, Samuel J. Klempner, Mark W. Turrentine, Anindya Chatterjee, Astra M. Liepa, Erwin Berthier and Terry A. Vik and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Academic Medicine.

In The Last Decade

Holly Knoderer

16 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Holly Knoderer United States 10 89 88 76 73 65 19 316
Halise Akça Türkiye 11 40 0.4× 57 0.6× 45 0.6× 72 1.0× 52 0.8× 49 412
Ayşe Kargılı Türkiye 12 70 0.8× 19 0.2× 51 0.7× 42 0.6× 30 0.5× 23 304
Sameer Gupta United States 9 56 0.6× 24 0.3× 45 0.6× 15 0.2× 44 0.7× 24 229
Guillaume Stoffels United States 10 74 0.8× 47 0.5× 96 1.3× 30 0.4× 11 0.2× 46 442
Nicolás Medrano Spain 11 28 0.3× 30 0.3× 28 0.4× 30 0.4× 17 0.3× 26 316
Yılmaz Yozgat Türkiye 10 84 0.9× 26 0.3× 55 0.7× 45 0.6× 27 0.4× 43 322
Susan Morgan Australia 10 40 0.4× 21 0.2× 40 0.5× 46 0.6× 27 0.4× 18 226
Natalie Lott Australia 9 62 0.7× 15 0.2× 52 0.7× 20 0.3× 19 0.3× 29 365
İsmail Bıyık Türkiye 11 64 0.7× 22 0.3× 49 0.6× 80 1.1× 37 0.6× 57 338
Hatice Işık Türkiye 11 73 0.8× 52 0.6× 32 0.4× 113 1.5× 40 0.6× 29 420

Countries citing papers authored by Holly Knoderer

Since Specialization
Citations

This map shows the geographic impact of Holly Knoderer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holly Knoderer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holly Knoderer more than expected).

Fields of papers citing papers by Holly Knoderer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holly Knoderer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holly Knoderer. The network helps show where Holly Knoderer may publish in the future.

Co-authorship network of co-authors of Holly Knoderer

This figure shows the co-authorship network connecting the top 25 collaborators of Holly Knoderer. A scholar is included among the top collaborators of Holly Knoderer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holly Knoderer. Holly Knoderer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
3.
Kalinsky, Kevin, Giampaolo Bianchini, Erika Hamilton, et al.. (2024). Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.. Journal of Clinical Oncology. 42(17_suppl). LBA1001–LBA1001. 29 indexed citations
4.
Lassaletta, Álvaro, Lucas Moreno, Chitose Ogawa, et al.. (2023). Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).. Journal of Clinical Oncology. 41(16_suppl). 10039–10039. 1 indexed citations
5.
Greengard, Emily, Noah Federman, Yanhong Zhou, et al.. (2023). Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).. Journal of Clinical Oncology. 41(16_suppl). TPS10068–TPS10068. 2 indexed citations
6.
Wickremsinhe, Enaksha, Erwin Berthier, Diego López de Castilla, et al.. (2022). Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry. The Journal of Applied Laboratory Medicine. 8(3). 535–550. 35 indexed citations
7.
Kalinsky, Kevin, Rachel M. Layman, Peter A. Kaufman, et al.. (2022). postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.. Journal of Clinical Oncology. 40(16_suppl). TPS1117–TPS1117. 8 indexed citations
8.
Catenacci, Daniel V.T., Joseph Chao, Kei Muro, et al.. (2021). Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. The Oncologist. 26(10). e1704–e1729. 16 indexed citations
9.
Mansoor, Wasat, Eric Roeland, Aafia Chaudhry, et al.. (2021). Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies. The Oncologist. 26(9). e1538–e1547. 27 indexed citations
10.
Klempner, Samuel J., Zev A. Wainberg, Kei Muro, et al.. (2020). Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study.. Journal of Clinical Oncology. 38(15_suppl). 4543–4543. 3 indexed citations
11.
Mansoor, Wasat, Eric Roeland, Aafia Chaudhry, et al.. (2020). Analysis of weight loss as a prognostic factor in patients (pts) with advanced gastric cancer from REGARD, RAINBOW and RAINFALL phase III studies.. Journal of Clinical Oncology. 38(4_suppl). 348–348. 1 indexed citations
12.
Knoderer, Holly, et al.. (2015). Characterization of Dronabinol Usage in a Pediatric Oncology Population. The Journal of Pediatric Pharmacology and Therapeutics. 20(6). 462–467. 30 indexed citations
13.
Creary, Susan E., Mark E. Heiny, James M. Croop, et al.. (2011). Clinical course of postthrombotic syndrome in children with history of venous thromboembolism. Blood Coagulation & Fibrinolysis. 23(1). 39–44. 28 indexed citations
14.
Knoderer, Chad A. & Holly Knoderer. (2011). Hyperphosphatemia in Pediatric Oncology Patients Receiving Liposomal Amphotericin B. The Journal of Pediatric Pharmacology and Therapeutics. 16(2). 87–91. 4 indexed citations
15.
Knoderer, Holly. (2009). Inclusion of Parents in Pediatric Subspecialty Team Rounds: Attitudes of the Family and Medical Team. Academic Medicine. 84(11). 1576–1581. 31 indexed citations
16.
Knoderer, Holly, et al.. (2009). Central nervous system involvement at the time of presentation in acute promyelocytic leukemia. Pediatric Blood & Cancer. 54(4). 603–605. 10 indexed citations
17.
Knoderer, Chad A., et al.. (2009). Recombinant Factor VIIa for Bleeding in Non-hemophiliac Pediatric Patients. The Journal of Pediatric Pharmacology and Therapeutics. 14(1). 38–47.
18.
Knoderer, Chad A., Holly Knoderer, Mark W. Turrentine, & Manjusha Kumar. (2006). Lepirudin Anticoagulation for Heparin‐Induced Thrombocytopenia After Cardiac Surgery in a Pediatric Patient. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(5). 709–712. 21 indexed citations
19.
Knoderer, Holly, Jason Robarge, & David A. Flockhart. (2006). Predicting asparaginase‐associated pancreatitis. Pediatric Blood & Cancer. 49(5). 634–639. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Halise Akça Breakdown of academic impact, for papers by Ayşe Kargılı Breakdown of academic impact, for papers by Sameer Gupta Breakdown of academic impact, for papers by Guillaume Stoffels Breakdown of academic impact, for papers by Nicolás Medrano Breakdown of academic impact, for papers by Yılmaz Yozgat Breakdown of academic impact, for papers by Susan Morgan Breakdown of academic impact, for papers by Natalie Lott Breakdown of academic impact, for papers by İsmail Bıyık Breakdown of academic impact, for papers by Hatice Işık
Rankless by CCL
2026